Retatrutide

Retatrutide reduced HbA1c by 1.69% to 1.94% versus 0.81% with placebo, with treatment differences of -0.88% to -1.12% (all p<0.0001).; Body weight decreased by 11.5% to 15.3% with retatrutide versus 2.6% with placebo.; Most adverse events were mild-to-moderate gastrointestinal events that subsided over time; discontinuations due to adverse events were 2-5% with retatrutide and 0% with placebo.; No severe hypoglycemia was reported; two deaths occurred in the retatrutide 4 mg group, both unrelated to the study drug.

Retatrutide is a triple agonist of GIP, GLP-1, and glucagon receptors.; The program includes two basket trials (TRIUMPH-1 and -2) with nested OSA/OA protocols, one CVD-focused trial (TRIUMPH-3), and one stand-alone OA trial (TRIUMPH-4).; Type I error rate is controlled at 0.05 across weight management and basket trials.; The design allows concurrent evaluation of retatrutide for obesity, OSA, and knee OA.

Retatrutide 8 mg (pooled) led to a 26.1% reduction in total fat mass, significantly greater than placebo (4.5% reduction).; Retatrutide 4 mg and 12 mg also significantly reduced fat mass compared to placebo (15.2% and 23.2% reductions, respectively).; Adverse events were similar across groups, with gastrointestinal events most common and no deaths reported.; Lean mass loss proportion was similar to other obesity treatments, indicating no disproportionate lean mass loss with retatrutide.

Obesity reduces life expectancy by 5-20 years and imposes a global economic burden of USD 2 trillion annually.; GLP-1 receptor agonists achieve 15-25% mean weight loss, reduce major adverse cardiovascular events by 20%, and lower T2D incidence by 72%.; Emerging therapies like oral GLP-1 agonists and triple-receptor agonists may improve tolerability and muscle preservation.; Challenges include high costs, supply shortages, gastrointestinal side effects, and weight regain after discontinuation.

Retatrutide activates GLP-1, GIP, and glucagon receptors, leading to weight reduction and improved glycemic control.; Animal studies show delayed gastric emptying, reduced food intake, and superior weight loss compared to other incretin-based therapies.; Phase I/II trials demonstrate dose-dependent weight loss, HbA1c reductions, and improvements in liver steatosis and diabetic kidney disease.; Common adverse effects are gastrointestinal and dose-related; ongoing Phase III TRIUMPH studies evaluate long-term safety and efficacy.

Females lost more weight than males overall (MD 1.04 kg; 1.69%) and across GLP-1RAs (MD 0.88 kg).; Greater weight reduction was associated with larger sex differences (meta-regression coefficient -0.19).; Obesity as an indication amplified the sex difference (MD 4.21 kg).; Dulaglutide and semaglutide showed significant sex differences, but exenatide did not.

Semaglutide 2.4 mg results in 15-17% mean weight loss and offers cardioprotection.; Tirzepatide, a dual GLP-1/GIP agonist, leads to up to 22.5% weight loss in phase 3 trials.; Combinations like cagrisema and retatrutide are in phase 3 trials and may surpass tirzepatide in weight loss.; Agents with different mechanisms, such as bimagrumab, are in early trials to improve body composition during weight loss.

Tirzepatide (15 mg weekly) led to 17.8% weight loss at 72 weeks; semaglutide (2.4 mg weekly) to 13.9% at 68 weeks; liraglutide (3.0 mg daily) to 5.8% at 26 weeks.; Retatrutide (12 mg weekly) produced the greatest weight loss of 22.1% at 48 weeks.; Adverse events occurred in 80-97% of GLP-1 RA groups vs. 63-100% with placebo, mostly gastrointestinal (47-84% vs. 13-63%).; Serious adverse events (0-10%) and discontinuations due to AEs (0-26%) were rare.

What is Retatrutide?

Retatrutide (LY3437943) is a synthetic peptide designed as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its mechanism of action integrates complementary metabolic effects: GLP-1 receptor activation enhances insulin secretion and del

How does Retatrutide work?

Triple GIP/GLP-1/glucagon receptor agonist in phase 3 trials showing the largest weight reductions of any incretin therapy to date.

What is the research status of Retatrutide?

Retatrutide is currently classified as clinical trials, with 170 research references on record. This is for research purposes only and is not medical advice.